{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:27:45Z","timestamp":1771918065884,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1038\/s41433-021-01493-2","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T17:04:19Z","timestamp":1615395859000},"page":"407-413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Vismodegib improves quality of life in patients with periocular locally advanced basal cell carcinoma: subgroup analysis, STEVIE trial"],"prefix":"10.1038","volume":"36","author":[{"given":"Assaf","family":"Gershoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alon","family":"Tiosano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meydan","family":"Ben Ishai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Barayev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-2694","authenticated-orcid":false,"given":"Guy","family":"J. Ben Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iftach","family":"Yassur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"key":"1493_CR1","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1056\/NEJMra044151","volume":"353","author":"AI Rubin","year":"2005","unstructured":"Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353:2262\u20139. https:\/\/doi.org\/10.1056\/NEJMra044151.","journal-title":"N Engl J Med"},{"key":"1493_CR2","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1001\/jamadermatol.2015.1188","volume":"151","author":"MM Asgari","year":"2015","unstructured":"Asgari MM, Moffet HH, Ray GT, Quesenberry CP. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998-2012. JAMA Dermatol. 2015;151:976\u201381. https:\/\/doi.org\/10.1001\/jamadermatol.2015.1188.","journal-title":"JAMA Dermatol"},{"key":"1493_CR3","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nrc2503","volume":"8","author":"EH Epstein","year":"2008","unstructured":"Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8:743\u201354. https:\/\/doi.org\/10.1038\/nrc2503.","journal-title":"Nat Rev Cancer"},{"key":"1493_CR4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/CCO.0b013e32835ff438","volume":"25","author":"A Sekulic","year":"2013","unstructured":"Sekulic A, Mangold AR, Northfelt DW, LoRusso PM. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol. 2013;25:218\u201323. https:\/\/doi.org\/10.1097\/CCO.0b013e32835ff438.","journal-title":"Curr Opin Oncol"},{"key":"1493_CR5","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","volume":"86","author":"N Basset-Seguin","year":"2017","unstructured":"Basset-Seguin N, Hauschild A, Kunstfeld R, Grob J, Dreno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334\u201348. https:\/\/doi.org\/10.1016\/j.ejca.2017.08.022.","journal-title":"Eur J Cancer"},{"key":"1493_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.soc.2018.05.008","volume":"27","author":"A Sitlinger","year":"2018","unstructured":"Sitlinger A, Zafar SY. Health-related quality of life: the impact on morbidity and mortality. Surgical Oncol Clin North Am. 2018;27:675\u201384. https:\/\/doi.org\/10.1016\/j.soc.2018.05.008.","journal-title":"Surgical Oncol Clin North Am"},{"key":"1493_CR7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/archdischild-2018-314951","volume":"103","author":"RJ Forsyth","year":"2018","unstructured":"Forsyth RJ. We have to talk about health-related quality of life. Arch Dis Child. 2018;103:913\u20134. https:\/\/doi.org\/10.1136\/archdischild-2018-314951.","journal-title":"Arch Dis Child"},{"key":"1493_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/bf00434740","volume":"5","author":"S Blackford","year":"1996","unstructured":"Blackford S, Roberts D, Salek MS, Finlay A. Basal cell carcinomas cause little handicap. Qual Life Res. 1996;5:191\u20134. https:\/\/doi.org\/10.1007\/bf00434740.","journal-title":"Qual Life Res"},{"key":"1493_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1684\/ejd.2018.3448","volume":"28","author":"J Hansson","year":"2018","unstructured":"Hansson J, Bartley K, Karagiannis T, Grob JJ, Kunstfeld R, Dreno B, et al. Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study. Eur J Dermatol. 2018;28:775\u201383. https:\/\/doi.org\/10.1684\/ejd.2018.3448.","journal-title":"Eur J Dermatol"},{"key":"1493_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/IOP.0b013e3182831bf3","volume":"29","author":"VT Yin","year":"2013","unstructured":"Yin VT, Pfeiffer ML, Esmaeli B. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma. Ophthalmic Plast Reconstructive Surg. 2013;29:87\u201392. https:\/\/doi.org\/10.1097\/IOP.0b013e3182831bf3.","journal-title":"Ophthalmic Plast Reconstructive Surg"},{"key":"1493_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.6004\/jadpro.2014.5.4.7","volume":"5","author":"NM Nix","year":"2014","unstructured":"Nix NM, Burdine O, Walker M. Vismodegib: first-in-class hedgehog pathway inhibitor for metastatic or locally advanced basal cell carcinoma. J Adv Practitioner Oncol. 2014;5:294\u20136. https:\/\/doi.org\/10.6004\/jadpro.2014.5.4.7.","journal-title":"J Adv Practitioner Oncol"},{"key":"1493_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1470-2045(15)70198-1","volume":"16","author":"N Basset-Seguin","year":"2015","unstructured":"Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dreno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16:729\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(15)70198-1.","journal-title":"Lancet Oncol"},{"key":"1493_CR13","doi-asserted-by":"publisher","unstructured":"Ben Ishai M, Tiosano A, Fenig E, Ben Simon G, Yassur I. Outcomes of Vismodegib for periocular locally advanced basal cell carcinoma from an open-label trial. JAMA Ophthalmol. 2020. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.1539.","DOI":"10.1001\/jamaophthalmol.2020.1539"},{"key":"1493_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.eye.6700234","volume":"17","author":"A Clarke","year":"2003","unstructured":"Clarke A, Rumsey N, Collin JR, Wyn-Williams M. Psychosocial distress associated with disfiguring eye conditions. Eye. 2003;17:35\u201340. https:\/\/doi.org\/10.1038\/sj.eye.6700234.","journal-title":"Eye"},{"key":"1493_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/09286586.2019.1611879","volume":"26","author":"AG Hamedani","year":"2019","unstructured":"Hamedani AG, VanderBeek BL, Willis AW. Blindness and visual impairment in the medicare population: disparities and association with hip fracture and neuropsychiatric outcomes. Ophthalmic Epidemiol. 2019;26:279\u201385. https:\/\/doi.org\/10.1080\/09286586.2019.1611879.","journal-title":"Ophthalmic Epidemiol"},{"key":"1493_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","volume":"30","author":"MM Chren","year":"2012","unstructured":"Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatologic Clin. 2012;30:231\u20136. https:\/\/doi.org\/10.1016\/j.det.2011.11.003.","journal-title":"Dermatologic Clin"},{"key":"1493_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3111\/13696998.2013.800822","volume":"16","author":"SL Shingler","year":"2013","unstructured":"Shingler SL, Garside J, Samanta K, Lear JT, Keohane S, Lloyd AJ. Utilities for advanced basal cell carcinoma. J Med Econ. 2013;16:777\u201383. https:\/\/doi.org\/10.3111\/13696998.2013.800822.","journal-title":"J Med Econ"},{"key":"1493_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s13555-015-0081-6","volume":"5","author":"AW Steenrod","year":"2015","unstructured":"Steenrod AW, Smyth EN, Bush EN, Chang AL, Arron ST, Helfrich YR, et al. A qualitative comparison of symptoms and impact of varying stages of basal cell carcinoma. Dermatol Ther. 2015;5:183\u201399. https:\/\/doi.org\/10.1007\/s13555-015-0081-6.","journal-title":"Dermatol Ther"},{"key":"1493_CR19","unstructured":"Alon Kahana M. Vismodegib for basal cell carcinoma. In: Kanaga Rajan P, editor. AAO Daily 2019. 2019."},{"key":"1493_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/bjo.2010.188425","volume":"95","author":"JM Durnian","year":"2011","unstructured":"Durnian JM, Noonan CP, Marsh IB. The psychosocial effects of adult strabismus: a review. Br J Ophthalmol. 2011;95:450\u20133. https:\/\/doi.org\/10.1136\/bjo.2010.188425.","journal-title":"Br J Ophthalmol"},{"key":"1493_CR21","unstructured":"McKee S. Roche\u2019s Erivedge no longer funded by the NHSPharmaTimes online. 2017."},{"key":"1493_CR22","unstructured":"Review P-COD. Final Reccomendation for Vismodegib (Erivedge) for Basal Cell Carcinoma pERC Meeting. January, 2013; Reconsideration Meeting: December 19, 2013."},{"key":"1493_CR23","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s40265-018-0948-9","volume":"78","author":"JE Frampton","year":"2018","unstructured":"Frampton JE, Basset-Seguin N. Vismodegib: a review in advanced basal cell carcinoma. Drugs. 2018;78:1145\u201356. https:\/\/doi.org\/10.1007\/s40265-018-0948-9.","journal-title":"Drugs"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01493-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01493-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01493-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T21:06:39Z","timestamp":1643749599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01493-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1493"],"URL":"https:\/\/doi.org\/10.1038\/s41433-021-01493-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"assertion":[{"value":"3 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was a secondary analysis of the STEVIE data and did not involve the recruitment of new participants. Therefore, institutional review board approval and patient consent were waived by our institutional protocol. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}